4 US IPOs planned for the week of Apr 21

The following IPOs are expected to price this week : 


Aldeyra Therapeutics ( ALDX ), a clinical-stage biotech developing treatments for rare skin and eye diseases, plans to raise $25 million by offering 2.3 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Aldeyra Therapeutics would command a market value of $75 million. Aldeyra Therapeutics, which was founded in 2004, booked $0 million in sales over the last 12 months. The Burlington, MA-based company plans to list on the NASDAQ under the symbol ALDX. Aegis Capital is the lead bookrunner on the deal. 

Quotient ( QTNT ), which is developing a diagnostics test for grouping and disease screening blood samples, plans to raise $50 million by offering 5.0 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Quotient would command a market value of $149 million. Quotient, which was founded in 2007, booked $19 million in sales over the last 12 months. The Midlothian, United Kingdom-based company plans to list on the NASDAQ under the symbol QTNT. UBS Investment Bank, Baird and Cowen & Company are the joint bookrunners on the deal. (Revised terms on 4/14/14. Previously planned to offer 5.0mm shares at $14-$16.) 



SCYNEXIS ( SCYX ), a biotech developing treatments for life-threatening fungal infections, plans to raise $55 million by offering 7.3 million shares at a price range of $7.00 to $8.00. At the midpoint of the proposed range, SCYNEXIS would command a market value of $143 million. SCYNEXIS, which was founded in 1999, booked $17 million in sales over the last 12 months. The Durham, NC-based company plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity are the joint bookrunners on the deal. (Revised terms on 4/2/14. Previously planned to offer 4.2mm shares at $12-$14.) 

Viggle (VGGL), a mobile app that rewards users for watching TV and listening to music, plans to raise $50 million by offering 2.1 million shares at a price of $23.50. At the midpoint of the proposed range, Viggle would command a market value of $313 million. Viggle, which was founded in 2011, booked $17 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol VGGL. Ladenburg Thalmann & Co. and Roth Capital are the lead bookrunners  on the deal. 

Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing. 
Last week, there were 10 IPO pricings . TriVascular Technologies ( TRIV ), which markets the smallest and most versatile stent grafts for endovascular aortic repair, was the week's winner, ending up 19% from its IPO price.
By Renaissance Capital,

Read more: http://www.nasdaq.com/article/4-us-ipos-planned-for-the-week-of-apr-21-cm345577#ixzz2zZQ6uNBZ